Back

Comprehensive Analysis of CRISPR Base Editing Outcomes for Multimeric Protein

Kabra, M.; Moosajee, M.; Newby, G.; Molugu, K.; Saha, K.; Liu, D.; Pattnaik, B. R.

2022-06-20 genetics
10.1101/2022.06.20.496792 bioRxiv
Show abstract

Point mutations in the KCNJ13 gene cause an autosomal recessive, childhood blindness, Leber congenital amaurosis (LCA16) due to a loss-of-function Kir7.1 channel. In the present study, we investigated the etiology of LCA16 caused by a KCNJ13 missense mutation (c.431T>C, p.Leu144Pro) and explored the activity of two cytosine base editors mRNAs (CBEs, BE4max-WTCas9, and evoCDA-SpCas9-NG) as a proof-of-concept therapeutic option. We observed the KCNJ13-related retinopathy phenotype in patients harboring L144P mutation. Our in-silico prediction and in vitro validation demonstrated that L144P mutation affects the channel function. We observed high on-target efficiency in the CBEs treated L144P mutant gene expressing HEK-293 cells. Strikingly, our evaluation of base editing efficacy using electrophysiology showed negligible channel function. We found that the editing bystander Cs in the protospacer region led to a missense change (L143F) in evoCDA edited cells and only silent changes in BE4max edited cells. Upon investigation of the effect of the synonymous codon, our extended analysis revealed distortion of mRNA structure, altered half-life, and/or low abundance of the cognate tRNA. We propose that KCNJ13-L144P mutation or other genes that share similar genetic complexity may be challenging to correct with the current generation of CRISPR base editors, and a combinational therapy using CRISPR base editors with a tighter editing window and requisite cognate-tRNA supplementation could be an alternative therapeutic approach to restore Kir7.1 channel function in LCA16 patients. Other options for hard-to-rescue alleles could employ homology-directed repair using CRISPR/Cas9 nucleases, Prime editing, and AAV-mediated gene augmentation.

Matching journals

The top 3 journals account for 50% of the predicted probability mass.

1
Molecular Therapy
71 papers in training set
Top 0.1%
42.2%
2
Nature Communications
4913 papers in training set
Top 25%
7.2%
3
Theranostics
33 papers in training set
Top 0.1%
4.2%
50% of probability mass above
4
ACS Chemical Biology
150 papers in training set
Top 0.4%
3.8%
5
EMBO Molecular Medicine
85 papers in training set
Top 0.9%
2.6%
6
Nucleic Acids Research
1128 papers in training set
Top 8%
2.6%
7
Scientific Reports
3102 papers in training set
Top 52%
2.0%
8
Frontiers in Genetics
197 papers in training set
Top 4%
1.8%
9
The CRISPR Journal
33 papers in training set
Top 0.1%
1.6%
10
eLife
5422 papers in training set
Top 46%
1.4%
11
Molecular Therapy - Nucleic Acids
24 papers in training set
Top 0.1%
1.4%
12
PLOS Genetics
756 papers in training set
Top 11%
1.3%
13
iScience
1063 papers in training set
Top 20%
1.3%
14
BMC Biology
248 papers in training set
Top 2%
1.2%
15
Cell Discovery
54 papers in training set
Top 4%
0.9%
16
Journal of Genetics and Genomics
36 papers in training set
Top 2%
0.8%
17
Cell Reports Physical Science
18 papers in training set
Top 0.7%
0.8%
18
Cell Proliferation
12 papers in training set
Top 0.3%
0.8%
19
ACS Chemical Neuroscience
60 papers in training set
Top 2%
0.8%
20
The American Journal of Human Genetics
206 papers in training set
Top 3%
0.8%
21
NAR Molecular Medicine
18 papers in training set
Top 0.2%
0.8%
22
Advanced Science
249 papers in training set
Top 18%
0.8%
23
Biomedicines
66 papers in training set
Top 3%
0.8%
24
Molecular Therapy Methods & Clinical Development
13 papers in training set
Top 0.1%
0.8%
25
Cell Genomics
162 papers in training set
Top 6%
0.8%
26
Communications Biology
886 papers in training set
Top 23%
0.8%
27
Genome Medicine
154 papers in training set
Top 9%
0.7%
28
Molecular Therapy - Methods & Clinical Development
38 papers in training set
Top 0.6%
0.7%
29
Molecular Therapy Nucleic Acids
32 papers in training set
Top 1.0%
0.5%